Double-Targeted immune cells aim to stop leukemia return
NCT ID NCT07575919
First seen May 11, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This study tests a new treatment using a patient's own immune cells, modified to attack two targets (CD22 and CD19) on leukemia cells. It is for people with standard-risk B-cell acute lymphoblastic leukemia who are already in remission. The goal is to see if this therapy is safe and can help prevent the cancer from coming back. About 20 participants will receive the treatment and be followed for 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.